Literature DB >> 16621479

Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.

Elin Jerremalm1, Inger Wallin, Jeffrey Yachnin, Hans Ehrsson.   

Abstract

Oxaliplatin undergoes extensive non-enzymatic chemical transformation in the body. Complexes with sulphur-containing compounds have previously been found in plasma from patients treated with oxaliplatin. We have studied the kinetics for the reactions between oxaliplatin and cysteine, methionine, and glutathione, by determination of the degradation of oxaliplatin using liquid chromatography with UV-detection. We also studied the degradation of oxaliplatin in plasma ultrafiltrate (PUF). For the degradation of oxaliplatin in the presence of glutathione, methionine, and cysteine, the second-order rate constants were 4.7M(-1)min(-1) (95% confidence interval [C.I.], 4.4-5.0M(-1)min(-1)), 5.5M(-1)min(-1) (95% C.I., 5.2-5.7M(-1)min(-1)), and 15M(-1)min(-1) (95% C.I., 14-17M(-1)min(-1)), respectively. The reaction rate was much faster than previously reported kinetics for cisplatin. The degradation rate of oxaliplatin in PUF was biphasic. The rate constant for the first phase varied from 9.5x10(-3) to 0.13min(-1) and for the second phase from (1.7 to 1.8)x10(-3)min(-1) in PUF from five healthy volunteers. The first hours of the degradation of oxaliplatin in PUF are accounted for by the degradation of oxaliplatin in a cocktail of sodium chloride and sulphur-containing compounds at physiological plasma concentrations. In conclusion, the rate of the reaction of oxaliplatin with three sulphur-containing compounds was faster for oxaliplatin than what is previously known for cisplatin. This may be important with respect to differences in the cellular effects of cisplatin and oxaliplatin treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621479     DOI: 10.1016/j.ejps.2006.03.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  10 in total

1.  Cimetidine as an organic cation transporter antagonist.

Authors:  Hans Ehrsson; Inger Wallin; Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

2.  Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion.

Authors:  H Mahteme; I Wallin; B Glimelius; L Påhlman; H Ehrsson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-18       Impact factor: 2.953

3.  Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration.

Authors:  Hans Ehrsson
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Oxaliplatin-induced ototoxicity in adjuvant setting for colorectal cancer: unusual side effect.

Authors:  Fatima Zahra Hijri; Samia Arifi; Naouar Ouattassi; Nawfal Mellas; Omar El Mesbahi
Journal:  J Gastrointest Cancer       Date:  2014-03

5.  HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).

Authors:  Filipa Lopes-Coelho; Sofia Gouveia-Fernandes; Luís G Gonçalves; Carolina Nunes; Inês Faustino; Fernanda Silva; Ana Félix; Sofia A Pereira; Jacinta Serpa
Journal:  Tumour Biol       Date:  2015-10-31

6.  Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.

Authors:  Khine Myint; Yan Li; James Paxton; Mark McKeage
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

Review 7.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

8.  Chemical Imaging of Platinum-Based Drugs and their Metabolites.

Authors:  Xin Liu; Amanda B Hummon
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

9.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

10.  Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.

Authors:  Amir Broomand; Elin Jerremalm; Jeffrey Yachnin; Hans Ehrsson; Fredrik Elinder
Journal:  J Negat Results Biomed       Date:  2009-01-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.